TY - JOUR
T1 - Plasma fibrinogen associates independently with total and cardiovascular mortality among subjects with normal and reduced kidney function in the general population
AU - Stack, A. G.
AU - Donigiewicz, U.
AU - Abdalla, A. A.
AU - Weiland, A.
AU - Casserly, L. F.
AU - Cronin, C. J.
AU - Nguyen, H. T.
AU - Hannigan, A.
N1 - Funding Information:
Dr Stack had full access to all of the data in the study and takes responsibility for the integrity of the data and data analysis. All collaborators participated in the study design, analysis, interpretation and preparation of the final manuscript. Ms Donigiewicz was a recipient of the 2011 Health Research Board (HRB) Summer Scholarship. Ms Jessica Jeong assisted with manuscript preparation. None of the authors have any relevant competing interests to disclose.
PY - 2014/9
Y1 - 2014/9
N2 - Background: The contribution of novel risk factors to mortality in chronic kidney disease remains controversial. Aim: To explore the association of plasma fibrinogen with mortality among individuals with normal and reduced kidney function. Methods: We identified 9184 subjects, age 40 and over from the Third National Health and Nutrition Examination Survey (1988-94) with vital status assessed through 2006. Plasma fibrinogen was modeled as continuous variable and in quartile groups (0 to <7.7, 7.7 to <9.0, 9.0 to <10.5 and ≥10.5 μmol/l) with total and cardiovascular mortality across categories of glomerular filtration rate (eGFR); <60, 60-90, >90 ml/min/1.73 m2 using Cox regression. Results: In multivariate analysis, the adjusted hazard ratio (HR) per 1 μmol/l (34 mg/dl) increase in fibrinogen was 1.07 [95% confidence interval (CI) 1.04-1.09] for total mortality and 1.06 (95% CI 1.03-1.09) for cardiovascular mortality. The adjusted HR for total mortality was 1.05 (1.01-1.09) for subjects with eGFR 60-90 ml/min/1.73 m2 and 1.06 (1.02-1.10) for subjects with eGFR <60 ml/min/1.73 m2. Subjects in the highest quartiles within each eGFR category; >90, 60-90 and <60 ml/min/1.73 m2 experienced HRs of 1.45 (95% CI 1.03-2.03), 1.35 (95% CI 1.00-1.83) and 1.72 (95% CI 1.14-2.58), respectively, compared with subjects in the lowest quartile group. The patterns were similar for cardiovascular mortality. Conclusions: Plasma fibrinogen associates with mortality among subjects with mild to moderate kidney impairment as it does in subjects with normal kidney function and should be considered a therapeutic target for cardiovascular risk reduction.
AB - Background: The contribution of novel risk factors to mortality in chronic kidney disease remains controversial. Aim: To explore the association of plasma fibrinogen with mortality among individuals with normal and reduced kidney function. Methods: We identified 9184 subjects, age 40 and over from the Third National Health and Nutrition Examination Survey (1988-94) with vital status assessed through 2006. Plasma fibrinogen was modeled as continuous variable and in quartile groups (0 to <7.7, 7.7 to <9.0, 9.0 to <10.5 and ≥10.5 μmol/l) with total and cardiovascular mortality across categories of glomerular filtration rate (eGFR); <60, 60-90, >90 ml/min/1.73 m2 using Cox regression. Results: In multivariate analysis, the adjusted hazard ratio (HR) per 1 μmol/l (34 mg/dl) increase in fibrinogen was 1.07 [95% confidence interval (CI) 1.04-1.09] for total mortality and 1.06 (95% CI 1.03-1.09) for cardiovascular mortality. The adjusted HR for total mortality was 1.05 (1.01-1.09) for subjects with eGFR 60-90 ml/min/1.73 m2 and 1.06 (1.02-1.10) for subjects with eGFR <60 ml/min/1.73 m2. Subjects in the highest quartiles within each eGFR category; >90, 60-90 and <60 ml/min/1.73 m2 experienced HRs of 1.45 (95% CI 1.03-2.03), 1.35 (95% CI 1.00-1.83) and 1.72 (95% CI 1.14-2.58), respectively, compared with subjects in the lowest quartile group. The patterns were similar for cardiovascular mortality. Conclusions: Plasma fibrinogen associates with mortality among subjects with mild to moderate kidney impairment as it does in subjects with normal kidney function and should be considered a therapeutic target for cardiovascular risk reduction.
UR - http://www.scopus.com/inward/record.url?scp=84900990713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84900990713&partnerID=8YFLogxK
U2 - 10.1093/qjmed/hcu057
DO - 10.1093/qjmed/hcu057
M3 - Article
C2 - 24633257
AN - SCOPUS:84900990713
SN - 1460-2725
VL - 107
SP - 701
EP - 713
JO - QJM: An International Journal of Medicine
JF - QJM: An International Journal of Medicine
IS - 9
ER -